收费全文 | 251526篇 |
免费 | 18358篇 |
国内免费 | 1126篇 |
耳鼻咽喉 | 2787篇 |
儿科学 | 6498篇 |
妇产科学 | 4597篇 |
基础医学 | 32937篇 |
口腔科学 | 4557篇 |
临床医学 | 25322篇 |
内科学 | 53562篇 |
皮肤病学 | 3386篇 |
神经病学 | 24298篇 |
特种医学 | 8399篇 |
外国民族医学 | 11篇 |
外科学 | 38519篇 |
综合类 | 3461篇 |
一般理论 | 318篇 |
预防医学 | 21415篇 |
眼科学 | 6558篇 |
药学 | 16964篇 |
6篇 | |
中国医学 | 361篇 |
肿瘤学 | 17054篇 |
2023年 | 1208篇 |
2022年 | 2341篇 |
2021年 | 5437篇 |
2020年 | 3265篇 |
2019年 | 5302篇 |
2018年 | 5955篇 |
2017年 | 4471篇 |
2016年 | 4959篇 |
2015年 | 5832篇 |
2014年 | 8609篇 |
2013年 | 11801篇 |
2012年 | 18018篇 |
2011年 | 18910篇 |
2010年 | 10581篇 |
2009年 | 9432篇 |
2008年 | 16606篇 |
2007年 | 17463篇 |
2006年 | 17317篇 |
2005年 | 17284篇 |
2004年 | 16198篇 |
2003年 | 15050篇 |
2002年 | 14064篇 |
2001年 | 2111篇 |
2000年 | 1615篇 |
1999年 | 2328篇 |
1998年 | 3075篇 |
1997年 | 2565篇 |
1996年 | 2191篇 |
1995年 | 2098篇 |
1994年 | 1745篇 |
1993年 | 1572篇 |
1992年 | 1265篇 |
1991年 | 1155篇 |
1990年 | 1006篇 |
1989年 | 978篇 |
1988年 | 968篇 |
1987年 | 947篇 |
1986年 | 956篇 |
1985年 | 970篇 |
1984年 | 1219篇 |
1983年 | 1125篇 |
1982年 | 1364篇 |
1981年 | 1312篇 |
1980年 | 1145篇 |
1979年 | 706篇 |
1978年 | 749篇 |
1977年 | 636篇 |
1976年 | 585篇 |
1975年 | 469篇 |
1974年 | 472篇 |
Methods: A retrospective cohort design and data from two US healthcare claims repositories were employed. The study population included patients who had non-metastatic cancer of the breast, colon/rectum, lung or ovaries, or non-Hodgkin’s lymphoma (NHL), and who received myelosuppressive chemotherapy regimens with an intermediate/high risk for FN. For each patient, the first cycle of the first course was characterized in terms of PP-CSF use and FN episodes. Crude incidence proportions for PP-CSF and FN during the first cycle were estimated by calendar quarter (2010–2016); multivariable logistic regression models were used to estimate quarter-specific adjusted mean probabilities of FN by PP-CSF use.
Results: The study population totaled 142,730 patients with breast cancer (61%), colorectal cancer (14%), NHL (11%), ovarian cancer (10%) or lung cancer (5%). PP-CSF use increased from 52% in 1Q2010 to 58% in 4Q2016; pegfilgrastim was the most commonly used agent (>96% across quarters). PP-CSF administration on the same day as chemotherapy ranged from 8 to 11% until 1Q2015, and increased to 64% by 4Q2016. Adjusted incidence proportions for FN in the first chemotherapy cycle ranged from 2.7% (95% CI: 2.3–3.0) to 3.7% (95% CI: 3.1–4.3) among those who did not receive PP-CSF, and was 2.6% (95% CI: 2.5–2.7) across quarters among those who received PP-CSF.
Conclusions: Although the use of PP-CSF is commonplace in current US clinical practice, underutilization in cancer patients receiving chemotherapy regimens with an intermediate/high risk for FN may still be an issue. Use of same-day PP-CSF increased markedly from the end of 2015, although this finding reflects (at least in part) increased uptake of pegfilgrastim delivered via an on-body injector as well as the recent change in clinical practice guidelines. Overall, patients receiving PP-CSF appear to have a lower risk of FN during the first cycle of chemotherapy. 相似文献